|
PMN
|
Hey Azzyma, I'm with you 100%, I should be banned for wrongthink. Sorry...
|
|
PMN
|
BottomBroker wrote: Maybe that'll free up some cash to put into a JV...
|
|
PMN
|
Of course not, but being top heavy is prerequisite for failing upwards in the...
|
|
PMN
|
Agreed, replacing management won't change anything right now. Doesn't...
|
|
PMN
|
bball67 wrote: I don't recall Promis devoting a PR solely to ALS. I...
|
|
PMN
|
Any PMN267 milestone reached is good news, but the statements from Cashman...
|
|
PMN
|
Trials targeted to avoid the CMS controversy would be a mistake, branding as...
|
|
PMN
|
FarmerBetty wrote: The truth hurts? It does indeed. Face it, independent...
|
|
PMN
|
These investment research sites offer a service but what's the value when...
|
|
PMN
|
He's 71, it will be interesting to see how the compensation deal splits...
|
|
PMN
|
I agree with Gary but I have this nagging doubt that any of us would be on...
|
|
PMN
|
The roadmap turned out wrong because the consultants couldn't execute...
|
|
PMN
|
"Argus Research Co. has received a flat fee from the company discussed...
|
|
PMN
|
Alzheon just raised another $50 million despite skepticism about Tolar's...
|
|
PMN
|
Seemed like a formality at this point. The FDA can't take any more stink...
|
|
PMN
|
Deadwood aside, I like the new quorum requirement and the virtual format...
|
|
PMN
|
Ptolemy would be proud. We just need to add some epicycles to the...
|
|
PMN
|
Yeah, that one sounded like a dead N-terminus. But I got stumped on their ALS...
|
|
PMN
|
Henry! welcome back Seems like you're assuming the epitope for 310 is not...
|
|
PMN
|
Prothena has the deals but what exactly is their science? Same diseases as...
|